Table 2.
OVV in combination with ICIs in different studies.
| OVV | Condition | ICIs (Combined treatment) | Ref. |
|---|---|---|---|
| ΔTK-ARMED-VACV | Pancrearic and hepatic cell lines | Coding sequence of anti-PD-1 and anti-4-1BB | (66) |
| hIL-7/mIL-12- VV | Melanoma, colon, lung, prostate adenocarcinoma, breast renal adenocarcinoma, melanoma, head and neck, glioblastoma neuroblastoma, hepatocellular carcinoma, esophageal, colorectal, gastric, bladder, kidney, ovarian, cervical and breast cancer |
Anti–programmed cell death-1 (PD-1) or anti–cytotoxic T lymphocyte antigen 4 (CTLA4) antibody | (22) |
| VV-iPDL1/GM | Osteosarcoma, adenocarcinoma, melanoma, murine lymphoma | Coding sequence of anti-PD-1 and GM-CSF | (63) |
| vvDD-IL15-Rα, | Mice bearing colon and ovarian cancer | Anti-PD-1 antibody | (67) |
| VV-SCFV-TIGIT | Breast, colon and hepatic cancer | SCFV of anti-TIGIT and anti-PD-1 | (68) |
| Western Reserve (WR) OVV | Melanoma Fibrosarcoma |
scFv, Fab and antibody forms of a hamster monoclonal IgG (namely J43) recognizing the murine PD-1 | (69) |
| GLV-1h68 | Soft-tissue Sarcoma | Recombinant rat anti-PD-1 protein | (70) |
| JX-594 | Murine bladder, Colon cancer, Lung | Anti-PD-1 antibody | (71) |
| CF33-hNIS-antiPDL1 | PDAC | Anti-PD-L1 | (72) |
| OVV-MnSOD | Lymphoma | Anti-PD-L1 antibody | (73) |
| vvDD | Colon and ovarian | Anti-PD-L1 antibody | (74) |
| JX | Colon | Anti-PD-1 antibody | (75) |